Found "HTA": 339 results
Sort by
Sort by
Z - A
Research for development of an optimal policy strategy for prevention and control of cervical cancer in Thailand
Cervical cancer is a global public health problem, with approximately 500,000 new cases are identified each year globally. The disease is the most common cancer in women in the developing world and its mortality is very high–nearly 300,000 per year, 80% of which are in resource-poor settings. Human papillomavirus (HPV) has been proven as a major
Report: Unit for Health Evidence and Policy (UHEP) Second Stakeholder Consultation and HTA Topic Prioritisation Workshop
This mission report summarises the activities and discussions during the second meeting of the Unit for Health Evidence and Policy (UHEP), held on September 1st, 2022. This meeting aimed to promote the understanding of Health Technology Assessment (HTA) topic prioritisation in Lao PDR and sharing Th
REPORT: TECHNICAL CAPACITY MAPPING ON HEALTH TECHNOLOGY ASSESSMENT (HTA) IN INDONESIA
This report is the outcome of a Technical Capacity Mapping exercise which was conducted by Health Intervention and Technology Assessment program (HITAP) Thailand with the support from International Decision Support Initiative (iDSI). It was performed with an aim to gather information about Hea
Report: Indonesian Delegation Study Visit to HITAP
The Indonesian government is strongly committed to Universal Health Coverage and acknowledges that health technology assessment (HTA) as an important tool for setting priorities for the health benefits package. Since the establishment of the HTA Committee, a number of Ministry of Health (MOH) and ac
Real-Word Evidence: How Does It Make HTA More Realistic? Is It Appropriate to Use?
Why do we need to make health technology assessment (HTA) more realistic? Is HTA not realistic nowadays?
The answers can be both YES and NO.HTA is a form of research for synthesising data to evaluate properties, effects, and impacts of health interventions and technology in diffe
Rapid Health Technology Assessment: A Cost-Utility and Budget Impact Analysis of Abiraterone Acetate for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel Therapy
Management of advanced prostate cancer, particularly in cases of metastatic castration-resistant prostate cancer (mCRPC), typically involves first-line treatment with the chemotherapeutic agent docetaxel. Nevertheless, disease progression following docetaxel therapy remains a major challenge, as there are currently no therapeutic options listed in
Priority setting for health innovation and Early Health Technology Assessment for supporting research and development of medical innovation in Thailand (Fiscal Year 2026)
The development of medical innovation is one of Thailand’s key strategic priorities as outlined in the 13th National Economic and Social Development Plan (2023–2027). Milestone 4 identifies Thailand’s ambition to become a high-value medical and wellness hub, with the goal of strengthening the country’s capacity to generate economic value fr
Priority setting for health innovation and Early Health Technology Assessment for supporting research and development of medical innovation in Thailand (Fiscal year 2025)
The development of medical innovation is one of Thailand’s key strategic priorities as outlined in the 13th National Economic and Social Development Plan (2023–2027). Milestone 4 identifies Thailand’s ambition to become a high-value medical and wellness hub, with the goal of strengthening the country’s capacity to generate economic value fr
10 / Page